Shanghai Zhongshan Hospital: Pancreatic Neoplasms trials

The registry lists 13 Pancreatic Neoplasms studies with Shanghai Zhongshan Hospital as lead sponsor. 13 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 8No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPCNot yet recruitingNCT07833241Phase 2
• A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal DataRecruitingNCT07561814
• Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic CancerRecruitingNCT07529626
• AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.Not yet recruitingNCT07208539Phase 2
• Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic CancerNot yet recruitingNCT07108504Phase 2
• The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical TrialRecruitingNCT06946901Phase 2
• Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic CancerNot yet recruitingNCT06941987
• An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic CancerRecruitingNCT06938282Phase 2
• Chemoradiotherapy in Elderly Patients with Locally Advanced Pancreatic Cancer (70+).Not yet recruitingNCT06844773
• Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic CancerNot yet recruitingNCT06166589Phase 2
• Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic CancerNot yet recruitingNCT05848154
• Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerRecruitingNCT05832892Phase 1/2
• Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic CancerNot yet recruitingNCT05562297Phase 2